Cargando…

Iron Deficiency Anemia in Inflammatory Bowel Disease: What Do We Know?

One of the most common extraintestinal manifestations of inflammatory bowel disease is iron deficiency anemia. It is often an untreated condition that significantly impairs patients' quality of life and elevates mortality and morbidity. Although it is often accompanied by mild symptoms (e.g., f...

Descripción completa

Detalles Bibliográficos
Autores principales: Resál, Tamás, Farkas, Klaudia, Molnár, Tamás
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8280493/
https://www.ncbi.nlm.nih.gov/pubmed/34277663
http://dx.doi.org/10.3389/fmed.2021.686778
_version_ 1783722644758069248
author Resál, Tamás
Farkas, Klaudia
Molnár, Tamás
author_facet Resál, Tamás
Farkas, Klaudia
Molnár, Tamás
author_sort Resál, Tamás
collection PubMed
description One of the most common extraintestinal manifestations of inflammatory bowel disease is iron deficiency anemia. It is often an untreated condition that significantly impairs patients' quality of life and elevates mortality and morbidity. Although it is often accompanied by mild symptoms (e.g., fatigue, lethargy), it can provoke severe health conditions, such as dyspnea, palpitation, angina, and mental disorders, and increases hospitalization and mortality rate as well. As anemia develops through several pathomechanisms, such as occult bleeding, chronic inflammation, and medicines (e.g., methotrexate), treating anemia effectively requires to manage the underlying pathological changes as well. Based on international publications and data, it is a frequent condition and more frequent in pediatrics. According to Goodhand et al., iron deficiency is present in more than 60% of children, whereas only 14% of them received oral iron therapy. Compared to adult patients, 22% have iron deficiency, and 48% of them received oral and 41% intravenous iron therapy. Miller et al. also highlighted that among young patients iron deficiency anemia is a frequent condition, as almost 50% of the patients were anemic in their cohort. European Crohn's and Colitis Organisation's statements are clear regarding the diagnosis of iron deficiency anemia, and the iron supplementation as well. Third-generation parenteral iron supplementations seem to be safer and more effective than oral iron pills. Oral iron in many cases cannot replace the iron homeostasis as well; furthermore, it can provoke dysbiosis, which can potentially lead to relapse. As a result, we claim that both oral and parenteral should be used more frequently; furthermore, intravenous iron could replace oral medicines as well in certain cases. Despite the fact that iron deficiency anemia is examined by many aspects, further questions can be raised. Can it imply underlying pathological lesions? Are both oral and intravenous iron therapy safe and effective? When and how are they used? We demand that more studies should be conducted regarding these issues.
format Online
Article
Text
id pubmed-8280493
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-82804932021-07-16 Iron Deficiency Anemia in Inflammatory Bowel Disease: What Do We Know? Resál, Tamás Farkas, Klaudia Molnár, Tamás Front Med (Lausanne) Medicine One of the most common extraintestinal manifestations of inflammatory bowel disease is iron deficiency anemia. It is often an untreated condition that significantly impairs patients' quality of life and elevates mortality and morbidity. Although it is often accompanied by mild symptoms (e.g., fatigue, lethargy), it can provoke severe health conditions, such as dyspnea, palpitation, angina, and mental disorders, and increases hospitalization and mortality rate as well. As anemia develops through several pathomechanisms, such as occult bleeding, chronic inflammation, and medicines (e.g., methotrexate), treating anemia effectively requires to manage the underlying pathological changes as well. Based on international publications and data, it is a frequent condition and more frequent in pediatrics. According to Goodhand et al., iron deficiency is present in more than 60% of children, whereas only 14% of them received oral iron therapy. Compared to adult patients, 22% have iron deficiency, and 48% of them received oral and 41% intravenous iron therapy. Miller et al. also highlighted that among young patients iron deficiency anemia is a frequent condition, as almost 50% of the patients were anemic in their cohort. European Crohn's and Colitis Organisation's statements are clear regarding the diagnosis of iron deficiency anemia, and the iron supplementation as well. Third-generation parenteral iron supplementations seem to be safer and more effective than oral iron pills. Oral iron in many cases cannot replace the iron homeostasis as well; furthermore, it can provoke dysbiosis, which can potentially lead to relapse. As a result, we claim that both oral and parenteral should be used more frequently; furthermore, intravenous iron could replace oral medicines as well in certain cases. Despite the fact that iron deficiency anemia is examined by many aspects, further questions can be raised. Can it imply underlying pathological lesions? Are both oral and intravenous iron therapy safe and effective? When and how are they used? We demand that more studies should be conducted regarding these issues. Frontiers Media S.A. 2021-07-01 /pmc/articles/PMC8280493/ /pubmed/34277663 http://dx.doi.org/10.3389/fmed.2021.686778 Text en Copyright © 2021 Resál, Farkas and Molnár. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Medicine
Resál, Tamás
Farkas, Klaudia
Molnár, Tamás
Iron Deficiency Anemia in Inflammatory Bowel Disease: What Do We Know?
title Iron Deficiency Anemia in Inflammatory Bowel Disease: What Do We Know?
title_full Iron Deficiency Anemia in Inflammatory Bowel Disease: What Do We Know?
title_fullStr Iron Deficiency Anemia in Inflammatory Bowel Disease: What Do We Know?
title_full_unstemmed Iron Deficiency Anemia in Inflammatory Bowel Disease: What Do We Know?
title_short Iron Deficiency Anemia in Inflammatory Bowel Disease: What Do We Know?
title_sort iron deficiency anemia in inflammatory bowel disease: what do we know?
topic Medicine
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8280493/
https://www.ncbi.nlm.nih.gov/pubmed/34277663
http://dx.doi.org/10.3389/fmed.2021.686778
work_keys_str_mv AT resaltamas irondeficiencyanemiaininflammatoryboweldiseasewhatdoweknow
AT farkasklaudia irondeficiencyanemiaininflammatoryboweldiseasewhatdoweknow
AT molnartamas irondeficiencyanemiaininflammatoryboweldiseasewhatdoweknow